These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 16773620)

  • 1. Economic burden of Parkinson's disease in a developing country: a retrospective cost analysis in Shanghai, China.
    Wang G; Cheng Q; Zheng R; Tan YY; Sun XK; Zhou HY; Ye XL; Wang Y; Wang Z; Sun BM; Chen SD
    Mov Disord; 2006 Sep; 21(9):1439-43. PubMed ID: 16773620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic burden of epilepsy in a developing country: a retrospective cost analysis in China.
    Hong Z; Qu B; Wu XT; Yang TH; Zhang Q; Zhou D
    Epilepsia; 2009 Oct; 50(10):2192-8. PubMed ID: 19583782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resource use and costs in a Swedish cohort of patients with Parkinson's disease.
    Hagell P; Nordling S; Reimer J; Grabowski M; Persson U
    Mov Disord; 2002 Nov; 17(6):1213-20. PubMed ID: 12465059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Costs of illness and care in Parkinson's disease: an evaluation in six countries.
    von Campenhausen S; Winter Y; Rodrigues e Silva A; Sampaio C; Ruzicka E; Barone P; Poewe W; Guekht A; Mateus C; Pfeiffer KP; Berger K; Skoupa J; Bötzel K; Geiger-Gritsch S; Siebert U; Balzer-Geldsetzer M; Oertel WH; Dodel R; Reese JP
    Eur Neuropsychopharmacol; 2011 Feb; 21(2):180-91. PubMed ID: 20888737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Costs of drug treatment in Parkinson's disease.
    Dodel RC; Eggert KM; Singer MS; Eichhorn TE; Pogarell O; Oertel WH
    Mov Disord; 1998 Mar; 13(2):249-54. PubMed ID: 9539337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug and treatment costs in Parkinson's disease patients in Sweden.
    Lökk J; Borg S; Svensson J; Persson U; Ljunggren G
    Acta Neurol Scand; 2012 Feb; 125(2):142-7. PubMed ID: 21470194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pramipexole v. levodopa as initial treatment for Parkinson's disease: a randomized clinical-economic trial.
    Noyes K; Dick AW; Holloway RG;
    Med Decis Making; 2004; 24(5):472-85. PubMed ID: 15358996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct costs of managing Parkinson's disease in India: concerns in a developing country.
    Ragothaman M; Govindappa ST; Rattihalli R; Subbakrishna DK; Muthane UB
    Mov Disord; 2006 Oct; 21(10):1755-8. PubMed ID: 16874759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Costs of Parkinson's disease in eastern Europe: a Czech cohort study.
    Winter Y; von Campenhausen S; Brozova H; Skoupa J; Reese JP; Bötzel K; Eggert K; Oertel WH; Dodel R; Ruzicka E
    Parkinsonism Relat Disord; 2010 Jan; 16(1):51-6. PubMed ID: 19665915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Parkinson's disease: cost-of-illness in an outpatient cohort].
    Reese JP; Winter Y; Balzer-Geldsetzer M; Bötzel K; Eggert K; Oertel WH; Dodel R; Campenhausen Sv
    Gesundheitswesen; 2011 Jan; 73(1):22-9. PubMed ID: 20229454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Social and economic cost of L-Dopa-induced dyskinesias in patients with Parkinson's disease].
    Maurel F; Lilliu H; Le Pen C
    Rev Neurol (Paris); 2001 May; 157(5):507-14. PubMed ID: 11438770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of health-care costs involved in treating people with and without Parkinson's disease in Southern Sydney, New South Wales, Australia.
    Cordato DJ; Schwartz R; Abbott E; Saunders R; Morfis L
    J Clin Neurosci; 2006 Jul; 13(6):655-8. PubMed ID: 16797991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-utility model of rasagiline in the treatment of advanced Parkinson's disease in Finland.
    Hudry J; Rinne JO; Keränen T; Eckert L; Cochran JM
    Ann Pharmacother; 2006 Apr; 40(4):651-7. PubMed ID: 16569799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Costs of Parkinson's disease and antiparkinsonian pharmacotherapy: an Italian cohort study.
    Winter Y; von Campenhausen S; Reese JP; Balzer-Geldsetzer M; Longo K; Spiga G; Boetzel K; Eggert K; Oertel WH; Dodel R; Barone P
    Neurodegener Dis; 2010; 7(6):365-72. PubMed ID: 20523028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic burden of schizophrenia: empirical analyses from a survey in Thailand.
    Phanthunane P; Whiteford H; Vos T; Bertram M
    J Ment Health Policy Econ; 2012 Mar; 15(1):25-32. PubMed ID: 22611090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Financial burden of hepatitis B-related diseases and factors influencing the costs in Shenzhen, China].
    Liang S; Zhang SX; Ma QS; Xiao HW; Lü QY; Xie X; Mei SJ; Hu DS; Zhou BP; Li B; Chen JF; Cui FQ; Wang FZ; Liang XF
    Zhonghua Liu Xing Bing Xue Za Zhi; 2010 Dec; 31(12):1340-5. PubMed ID: 21223660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Burden of illness in Parkinson's disease.
    Huse DM; Schulman K; Orsini L; Castelli-Haley J; Kennedy S; Lenhart G
    Mov Disord; 2005 Nov; 20(11):1449-54. PubMed ID: 16007641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment patterns and associated costs with Parkinson's disease levodopa induced dyskinesia.
    Suh DC; Pahwa R; Mallya U
    J Neurol Sci; 2012 Aug; 319(1-2):24-31. PubMed ID: 22664154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence and cost of medication nonadherence in Parkinson's disease: evidence from administrative claims data.
    Davis KL; Edin HM; Allen JK
    Mov Disord; 2010 Mar; 25(4):474-80. PubMed ID: 20131374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Impact of motor and non-motor symptoms on the direct costs of Parkinson's disease].
    Cubo E; Martínez Martin P; González M; Frades B;
    Neurologia; 2009; 24(1):15-23. PubMed ID: 19003550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.